Trial
NCT03481556
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Oncopeptides AB
Collaborators
—
Condition
Multiple Myeloma
Intervention
Melphalan flufenamide (Melflufen)
Why stopped
The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-19